[Effect of bencyclane in obliterative arterial diseases].
D000368:Aged; D001162:Arteriosclerosis Obliterans / Q000188:drug therapy; D001775:Blood Circulation / Q000187:drug effects; D002561:Cerebrovascular Disorders / Q000188:drug therapy; D003508:Cycloheptanes / Q000627:therapeutic use*; D003925:Diabetic Angiopathies / Q000188:drug therapy; D005650:Fumarates / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009497:Neurotic Disorders / Q000188:drug therapy; D009539:Nicotinic Acids / Q000627:therapeutic use; D009991:Oscillometry; D010208:Papaverine / Q000627:therapeutic use; D010276:Parasympatholytics / Q000627:therapeutic use*; D011437:Propylamines / Q000627:therapeutic use*; D012039:Regional Blood Flow; D012881:Skin Temperature / Q000187:drug effects; D013806:Theophylline / Q000627:therapeutic use; D013919:Thromboangiitis Obliterans / Q000188:drug therapy; D013927:Thrombosis / Q000188:drug therapy; D014149:Tranquilizing Agents / Q000627:therapeutic use; D014652:Vascular Diseases / Q000188:drug therapy*
D003508:Cycloheptanes; D005650:Fumarates; D009539:Nicotinic Acids; D010276:Parasympatholytics; D011437:Propylamines; D014149:Tranquilizing Agents; D013806:Theophylline; D010208:Papaverine
Die Wirkung von Bencyclan auf obliterative arterielle Erkrankungen.